Clinic Directory — coming soon. Are you an Australian peptide clinic?Apply to be listed →
Independent · Australian · Education only — not medical adviceAboutEditorial standardsHow we review
HomeEncyclopediaKPV

KPV

Anti-inflammatory tripeptide

Research / unapproved

What it is

A short peptide fragment (lysine-proline-valine) studied for anti-inflammatory effects, including in the gut.

What the evidence shows

Pre-clinical and early research interest in inflammation; robust human evidence is lacking.

Safety & reported risks

Unregulated supply with unknown quality and no established human safety profile.

Status in Australia

Not ARTG-approved. Online supply is not a lawful pathway for human use.

How it’s lawfully accessed

No lawful consumer supply. Not registered for human use.

Related peptides

BPC-157Body Protection CompoundNot ARTG-approvedThymosin Alpha-1Immune-modulating peptideCompounded useLarazotideTight-junction regulator (investigational)Investigational

Sources & further reading

This entry is general information about KPV, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.

Written by The Peptides.au editorial team
Editorial review Checked against current TGA, ARTG and AHPRA public guidance
Last updated 1 June 2026

This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.